Lonigutamab is under clinical development by Acelyrin and currently in Phase II for Graves’ Ophthalmopathy. According to GlobalData, Phase II drugs for Graves’ Ophthalmopathy have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lonigutamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lonigutamab overview

VB-421 is under development for the treatment of thyroid eye disease (TED, Graves ophthalmopathy) and other autoimmune, inflammatory and fibrotic disorders. The drug candidate is a humanized immunoglobulin G1 (IgG1) monoclonal antibody, administered through subcutaneous route. It acts by targeting insulin like growth factor 1 receptor (IGF-1R).

Acelyrin overview

Acelyrin is a biopharma company that identifies, acquires, and accelerates the development and commercialization of transformative medicines. It focuses on creating value for patients and shareholders. The company’s products include izokibep, Lonigutamab (anti-IGF-1R), XLRN-517 (anti-C-KIT). Acelyrin pipeline treats hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, uveitis, thyroid eye disease, and chronic urticaria.

For a complete picture of Lonigutamab’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.